Somatic mutations in DNMT3A are one of the most prevalent genetic abnormalities found in acute myeloid leukemia (AML) patients. A new study by Guryanova et al. sheds mechanistic insight into how the most common DNMT3A variant protein contributes to AML using a combination of mouse genetics and primary patient samples.

Original languageEnglish
Pages (from-to)7-8
Number of pages2
JournalCell Stem Cell
Issue number1
StatePublished - Jan 5 2017


Dive into the research topics of 'Dominating the Negative: How DNMT3A Mutations Contribute to AML Pathogenesis'. Together they form a unique fingerprint.

Cite this